Navigation Links
AlphaRx Provides Corporate and Development Update
Date:5/20/2008

MARKHAM, ON, May 20 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, is pleased to provide shareholders with an update on recent corporate developments.

TSX Venture Exchange Application

--------------------------------

AlphaRx is seeking a listing with the TSX Venture Exchange. Research Capital Corporation is sponsoring the application. AlphaRx is in the process of raising up to $1,800,000 U.S. via a private placement in conjunction with the listing application. AlphaRx has been in correspondence with the TSX Venture Exchange and has responded to all comments raised to-date.

Corporate Website

-----------------

AlphaRx is working on a new and improved corporate website which will reflect all current business focus. This new website will be launched some time in June.

Product Development

-------------------

AlphaRx's current focus is on the development of "nanobiotics" for the treatment of severe pneumonias. AlphaRx's high-priority development programs include Vansolin(TM) and Zysolin(TM).

Vansolin(TM), a specially-formulated Vancomycin nano-particulate formulation, is intended for the treatment of severe pneumonias caused by MRSA (Methicillin Resistant Staphylococcus Aureus) pathogens. Vansolin(TM) is undergoing pivotal animal studies. The Company will make a go/no go decision based on the outcome on these studies which will be available by mid-July.

Zysolin(TM), a specially-formulated Tobramycin nano-particulate formulation, intended for the treatment of severe pneumonias caused by gram negative pathogens such as Psedomonas Aeruginosa. The Company is developing Zysolin(TM) as a primary therapy for Cystic Fibrosis and an adjunctive therapy for ventilated patients with hospital-acquired, Gram-negative pneumonias. Zysolin(TM) is undergoing pivotal animal studies.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company's product candidates address various pharmaceutical markets, including inflammation, tuberculosis and pneumonia.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.

Copyright @ 2008. AlphaRx Inc.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRxs Indaflex(TM) Continues its Clinical Development
2. AlphaRx CEO Accumulates More Company Shares
3. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
4. AlphaRx Announces Debt Conversion
5. AlphaRx To Present at 47th Annual ICAAC
6. PA Health Department Provides Hepatitis B Vaccinations, Discusses Risk Factors
7. Cipher provides regulatory update for CIP-TRAMADOL ER
8. Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture
9. InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results
10. Revised AVMA Policy on Castrating and Dehorning Cattle Provides Additional Guidance for Managing Pain
11. Dubai Provides Aid for Cyclone Nargis Victims In Myanmar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 2016 , ... After enjoying record-breaking attendance at its last ... 33rd Annual Issues & Research Conference, March 2-3, 2017, at the Westin ... is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." 2016 ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused on ... efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, Jr. ... honored to team up with Upstage Lung Cancer in order to make major strides ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... Peachtree City, Ga (PRWEB) , ... December 08, ... ... and moving as soon after surgery as possible. With this in mind, SIGVARIS ... vein thrombosis (DVT or blood clot) during bed rest and provide the benefits ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... offices headquartered in Jefferson County, is announcing the launch of a charity drive ... The number of homeless women and children in Birmingham has grown steadily since ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) has been recognized ... Top Workplaces National Standard. To learn more about ... ... Inc.) ... survey administered by WorkplaceDynamics, LLC, a research firm specializing in organizational ...
(Date:12/8/2016)... Research and Markets has announced the addition ... Adhesion Type, Application, Usability - Forecast to 2025" report to ... , , ... poised to grow at a CAGR of around 3.2% from 2015 ... witnessing include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research ...
(Date:12/8/2016)... Dec. 8, 2016  Pennsylvania Physician General Dr. ... and Alcohol Programs Gary Tennis released ... known as benzodiazepines, developed with the help of ... medications that are frequently prescribed for anxiety or ... used with opioid pain medications, benzodiazepines pose a ...
Breaking Medicine Technology: